The month of September 2019 saw the publication of data drawn from the APST network on the use of nabiximols in the treatment of spasticity in Amyotrophic Lateral Sclerosis (ALS).
Please follow this link to view the corresponding article in the journal `BMC Neurology´:
Performed in 2017, the study now published shows that use of nabiximols in ALS is highly differentiated. The data give rise to the conclusion that two different use scenarios prevail in ALS: patients with high frequency use for intensive symptom control as well as patients with reduced medication intake on a need basis. The analysis of the patients’ self-rating results showed that patient satisfaction with nabiximols was good.
We would like to express our thanks to all our patients for taking part in this study by donating their data! With this data donation you greatly contributed to a better understanding of the treatment of spasticity in ALS.